MK 1308

Drug Profile

MK 1308

Alternative Names: MK-1308

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Merck AG
  • Class Antineoplastics; Biological factors
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 31 May 2017 Preclinical trials in Solid tumours in Germany (IV) before May 2017 (NCT03179436)
  • 31 May 2017 Merck plans a phase I trial of MK 1308 in combination with pembrolizumab for Solid tumours (NCT03179436)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top